




EPO41A3250



INVESTOR IN PEOPLE



The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

Stephen Hinchley
2 September 2004

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

NOT AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)THE PATENT OFFICE
CF
- 2 DEC 2003The Patent Office1/77
02DE03 E56482-1000866
P0177700 0.00-0327901.5

RECEIVED BY FAX

Request for grant of a patent
(See the notes on the back of this form. You can also
get an explanatory leaflet from the Patent Office to
help you fill in this form.)The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

| | | |
|---|---|--|
| 1. Your reference | GB Case | BT/3-22349/P1 |
| 2. Patent application number <i>(The Patent Office will fill in this part)</i> | 0327901.5 - 2 DEC 2003 | |
| 3. Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i> | Ciba Specialty Chemicals Water Treatments Limited Cleckheaton Road Low Moor Bradford West Yorkshire BD12 0JZ 758 5391005. | |
| Patent ADP number <i>If you know it</i> If the applicant is a corporate body, give the country/state of its incorporation | | |
| 4. Title of invention | PROCESS FOR PRODUCING POLYMERS | |
| 5. Name of your agent <i>If you have one</i> "Address for service" in the United Kingdom to which all correspondence should be sent <i>(including the postcode)</i> | Ciba Specialty Chemicals Water Treatments Limited Patents Department PO Box 38 Cleckheaton Road Low Moor Bradford West Yorkshire BD12 0JZ 07585391002 ✓ | |
| 6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and <i>If you know it</i> the or each application number | Country | Priority application number <i>If you know it</i> |
| 7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application | Number of earlier application Date of filing (day/month/year) | |
| 8. Is a statement of inventorship and of right to grant of a patent required in support of this request? <i>(Answer 'Yes' if:</i> | YES | |
| <i>a) any applicant named in part 3 is not an inventor, or</i> | | |
| <i>b) there is an inventor who is not named as an applicant, or</i> | | |
| <i>c) any named applicant is a corporate body. (see note (d))</i> | | |

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 17 /

Claim(s) 2 /

Abstract 1 /

Drawing(s) -

OF

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify) -

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

02 December 2003

Catherine Choppen

12. Name and daytime telephone number of person to contact in the United Kingdom

Catherine Choppen

01274 417446

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0845 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.

Process for Producing Polymers

The present invention relates to a process for making polymers of ethylenically unsaturated monomers. In particular the invention concerns processes in which

5 the ethylenically unsaturated monomers are manufactured using a biocatalyst.

It is well known to employ biocatalysts, such as microorganisms that contain enzymes, for conducting chemical reactions, or to use enzymes that are free of

microorganisms. It is known that various ethylenically unsaturated monomers

10 can be prepared by converting a substrate starting material into the desired monomer by use of a biocatalyst.

Nitrile hydratase enzymes are known to catalyse the hydration of nitriles directly to the corresponding amides. Typically nitrile hydratase enzymes can be

15 synthesized by a variety of microorganisms, for instance microorganisms of the genus *Bacillus*, *Bacteridium*, *Micrococcus*, *Brevibacterium*, *Corynebacterium*, *Pseudomonas*, *Acinetobacter*, *Xanthobacter*, *Streptomyces*, *Rhizobium*, *Klebsiella*, *Enterobacter*, *Erwinia*, *Aeromonas*, *Citrobacter*, *Achromobacter*, *Agrobacterium*, *Pseudonocardia*, *Rhodococcus* and *Comomonas*.

20 Much has been described that relates to the synthesis of nitrile hydratase within microorganisms. Arnaud et al., Agric. Biol. Chem. 41: (11) 2183-2191 (1977) describes the characteristics of an enzyme they refer to as 'acetonitrilase' from *Brevibacterium* sp R312 which degrades acetonitrile to acetate via the amide intermediate. Asano et al., Agric. Biol. Chem. 46: (5) 1183-1189 (1982) isolated

25 *Pseudomonas chlororaphis* B23 which produced nitrile hydratase to catalyse the conversion of acrylonitrile to acrylamide, generating 400 g/L acrylamide.

30 Various strains of the *Rhodococcus rhodochrous* species have been found to very effectively produce nitrile hydratase enzyme. EP-0 307 926 describes the culturing of *Rhodococcus rhodochrous*, specifically strain J1 in a culture

- medium that contains cobalt ions. The nitrile hydratase can be used to hydrate nitriles into amides, and in particular the conversion of 3-cyanopyridine to nicotinamide. In one embodiment an amide is produced in a culture medium of the microorganism in which a substrate nitrile is present. In another embodiment
- 5 a substrate nitrile is added to the culture medium in which a nitrile hydratase has been accumulated to conduct the hydration reaction. There is also a description of isolating the microorganism cells and supporting them in a suitable carrier, for instance by immobilisation, and then contacting them with a substrate. Rhodococcus rhodochrous J1, is also used commercially to
- 10 manufacture acrylamide monomer from acrylonitrile and this process has been described by Nagasawa and Yamada Pure Appl. Chem. 67: 1241-1256 (1995). EP-A-0362829 describes a method for cultivating bacteria of the species Rhodococcus rhodochrous comprising at least one of urea and cobalt ion for preparing the cells of Rhodococcus rhodochrous having nitrile hydratase
- 15 activity. Specifically described is Rhodococcus rhodochrous J1.
- Leonova et al., Appl. Biochem. Biotechnol. 88: 231-241 (2000) entitled, "Nitrile Hydratase of Rhodococcus", describes the growth and synthesis of nitrile hydratase in Rhodococcus rhodochrous M8. The NH₃ synthesis of this strain is
- 20 induced by urea in the medium, which is also used as a nitrogen source for growth by this organism. Cobalt is also required for high nitrile hydratase activity. This literature paper looks at induction and metabolic effects in the main.
- 25 Leonova et al., Appl. Biochem. Biotechnol. 88: 231-241 (2000) also states that acrylamide is produced commercially in Russia using Rhodococcus rhodochrous M8. Russian patent 1731814 describes Rhodococcus rhodochrous strain M8.

Rhodococcus rhodochrous strain M33 that produces nitrile hydratase without the need of an inducer such as urea is described in US-A-5827699. This strain of microorganism is a derivative of Rhodococcus rhodochrous M8.

5 The production of acrylamide monomer in particular is desirable via the biocatalytic route. WO-A-02/088373 describes a method and device for producing an aqueous acrylamide solution. A recycling loop containing a heat exchanger is used to remove heat of reaction and also to control the dosing of acrylonitrile.

10 WO-A-02/088371 describes a method and device for producing an aqueous acrylamide solution in which FTIR is used to monitor and control the reaction.

15 WO-A-02/50297 describes a process for producing an amide compound, one example of an amide being acrylamide using a microbial catalyst in which the catalyst is not entrapped. Therefore the free cell process can be carried out as a batch or continuous reaction.

20 In the review publication by Yamada and Kobayashi Biosci. Biotech. Biochem. 60: (9) 1391-1400 (1996) titled "Nitrile Hydratase and its Application to Industrial Production of Acrylamide" a detailed account of the development of a biocatalytic route to acrylamide is described. Three successively better catalysts and their characteristics for acrylamide production and in particular the third generation catalyst Rhodococcus rhodochrous J1 are described in some detail.

25 It is also known to produce ammonium acrylate directly from acrylonitrile by the action of a nitrilase enzyme. WO-A-9721827 describes producing a concentrated solution of ammonium (meth) acrylate which is substantially free of (meth) acrylonitrile by the enzymic hydrolysis of (meth) acrylonitrile in the presence of water using a nitrilase enzyme which has a Km for (meth)

acrylonitrile of below 500 micro moles and Ki for ammonium (meth) acrylate above 100,000 micro moles. The enzyme can be obtained from a *Rhodococcus rhodochrous* microorganism.

- Nagasawa et al., *Appl. Microbiol. Biotechnol.* 34: 322-324 (1990) also describe
5 the use of the nitrilase of *Rhodococcus rhodochrous* J1 for the synthesis of acrylic and methacrylic acid. They looked at the effects of temperature, acrylonitrile concentration and pH conditions on the reaction.

- Nitrilase has also been used to catalyse the selective hydrolysis of dinitriles as
10 is described by Bengis-Garber and Gutman in *Appl. Microbiol. Biotechnol.* 32: 11-16 (1989). Their organism *Rhodococcus rhodochrous* NCIMB 11216 was used to selectively convert in particular fumaronitrile to 3-cyanoacrylic acid.

- The use of a combination of nitrile hydratase and amidase has often been
15 described for the formation of carboxylic acid from the corresponding nitrile. For instance US-A-2003/0148480 describes the use of the nitrile hydratase and amidase of *Comamonas testosteroni* 5-MGAM-4D for the formation of acrylic and methacrylic acid with high yields and specificities being obtained.

- 20 It is standard practice to remove the biocatalytic cells from the growth medium before using the biomass to produce the monomers in order to avoid contamination of the monomer by impurities that could adversely affect the polymerisation.

- 25 It is generally accepted that even small quantities of impurities can affect the polymerisation of monomers or prevent polymerization taking place at all [k c1]. For instance initiating systems used for polymerisation are used in tiny amounts and therefore it would require only small amounts of impurities to inactivate them, stopping or short-stopping the polymerisation. Such impurities may result
30 in branching, cross-linking, chain termination or other effects on the polymer. Although it is known to purposely introduce small quantities of specific substances to induce chain transfer, branching or cross-linking during

polymerisation, these substances are introduced in a controlled manner into an otherwise substantially pure monomer in order to bring about a particular molecular structure. Recent developments in polymerisation techniques have made it possible to start from essentially pure monomers and introduce trace amounts of chemical additives to form polymers exhibiting extremely high molecular weights or polymers having a particular molecular structure.

Consequently it is possible to provide polymers which exhibit properties that are particularly suitable for specific applications, for instance dewatering of suspended solids to provide improved cake solids or in the field of papermaking improved combination of retention, drainage and formation.

It is known to polymerise ethylenically unsaturated monomers in the presence of a biocatalyst. For instance, it is known from WO-A-92/05205 that polyacrylamides with reduced levels of free acrylamide can be prepared by introducing an amidase enzyme into the monomer mixture prior to polymerisation. In this process the microbial cells containing amidase are separated from the fermentation broth. The amidase biocatalyst is not included in the biocatalytic step that forms the monomer but is added in a separate step. An amidase suspension was used in relatively small quantities such that residual levels of acrylamide in the formed polymer would be removed. The polymerisation process employed relatively high levels of initiator and low molecular weight polymers that were used for soil stabilisation were formed.

WO-A-97/06248 describes a process for the production of high stability amidase or nitrilase using a continuous culture under carbon limitation using a carbon source, which includes, respectively, either an amide or nitrile. The amidase made by this process is effective for converting (meth) acrylamide to ammonium (meth) acrylate, for instance in or after the polymerisation of acrylamide. Therefore the amidase is combining with (meth) acrylamide monomer in order to form ammonium acrylate monomer, or the amidase is combined with poly (meth) acrylamide in order to convert residual free (meth) acrylamide into

ammonium (meth) acrylate. There is also disclosure of combining the amidase enzyme and/or microorganism in the polymerisable mixture containing acrylamide and then polymerising to form the polymer and wherein the residual (meth) acrylamide content is reduced. In this process the amidase biocatalyst 5 does not form the monomer to be polymerised but is added in a separate step.

By their very nature impurities tend to be variable and give rise to unexpected and usually undesired effects on the polymer. Even small amounts of such 10 impurities may adversely affect the molecular structure of the polymer and in such circumstances would render the polymer product unsuitable for the intended application.

It is therefore standard practice to avoid the presence of contaminants in 15 monomers to be polymerised in order to prevent changes to the intended molecular structure and properties of the polymer. This is true whether the monomer has been manufactured using a synthetic catalyst or a biocatalyst. However, biological manufacture of monomers presents an increased risk of contamination from cellular material and the fermentation broth.

20 Contaminants that should normally be avoided include sugars, amino acids, metal salts, and polysaccharides, proteins and other organic products present, either from the medium used to generate the biomass or as spent medium, or as a metabolite from the growing cells or cellular material itself or degradation products arising from cell lysis and breakdown.

25 WO-A-02/088372 describes a method and device for producing an aqueous acrylamide solution using a biocatalyst. The process involves a separation method for removing the biocatalyst from the acrylamide product. This method involves the use of a centrifuge and optionally in combination with flocculation to 30 remove the biocatalyst. The biocatalyst is washed with water to remove residual monomer and the water is then used in the next bioconversion reaction.

Maestracci et al., Adv. Biochem. Eng. Biotechnol. 36: 69-115 (1988) describes Brevibacterium sp R312 to convert α -aminonitriles to their corresponding amino acids. The products were separated by well-known techniques including

- 5 removal of the cells by centrifugation followed by crystallisation.

Nagasawa et al., Appl. Microbiol. Biotechnol. 34: 322-324 (1990) concerns the production of acrylic acid and methacrylic acid using Rhodococcus rhodochrous J1 nitrilase. The reaction used whole cells of J1 in a solution of buffer to which 10 acrylonitrile was introduced. This paper reports that 39% acrylic acid was achieved. The reaction mixture was centrifuged to remove the cells and the acrylic acid and methacrylic acid were isolated from reaction mixture using diethyl ether.

15 The removal of biocatalyst and associated fermentation materials however from the monomer requires additional processing which can be costly and time-consuming. Consequently it would be desirable to more cost effectively provide polymer products exhibiting specifically designed features using biologically produced monomer.

20 According to the present invention we provide a process for preparing a polymer of an ethylenically unsaturated monomer, in which the monomer is obtainable from a biocatalytic or a fermentation process, and wherein the monomer contains cellular material and/or components of a fermentation broth, forming 25 the polymer by polymerising the ethylenically unsaturated monomer or a monomer mixture comprising the ethylenically unsaturated monomer, wherein there is substantially no removal of the cellular material and/or components of the fermentation broth from the ethylenically unsaturated monomer.

30 Desirably the ethylenically unsaturated monomer can be prepared by biocatalytically converting a suitable substrate that is capable of being

converted into the ethylenically unsaturated monomer. Typically the substrate is brought into contact with a biocatalyst and thereby converting the substrate into the ethylenically unsaturated monomer containing the cellular material and optionally components of a fermentation. Alternatively the ethylenically unsaturated monomer can be produced as a product of the fermentation process.

We have found that it is possible to manufacture polymers having specifically designed features and properties without the need for removing either the biocatalyst or the fermentation broth. Furthermore, the process enables ethylenically unsaturated monomers to be manufactured using a biocatalyst, which desirably results in high conversion of the substrate compound to form monomer in high yield exhibiting very low concentrations of the substrate compound or by-products. It would be generally expected that the presence of either the biocatalyst or the fermentation broth would have a detrimental effect on the polymerisation and the final polymer product that is formed. However, contrary to these expectations polymerising the monomer in the presence of the biocatalyst or the fermentation broth results in the desired polymers without any impairment.

Therefore, according to the present invention it would be possible to avoid removal of either the biocatalyst or the fermentation broth. Therefore it would be possible to avoid separation of the biocatalyst from the fermentation broth such that the monomer is polymerised in the presence of both the biocatalyst and the fermentation broth. Alternatively, the biocatalyst may be removed from the mixture, for instance by an in-line filter or by centrifugation or by flocculation, such that the monomer is polymerised in the presence of the fermentation broth but substantially in the absence of the biocatalyst. It may also be possible to solely remove the fermentation broth prior to the biocatalyst being used to form the monomer, such that the monomer is polymerised in the presence of biocatalyst. However, it is preferred that neither the biocatalyst nor the

fermentation broth are removed from the monomer prior to polymerisation. Consequently, the process would then avoid the processing step that would be required to remove the biocatalyst from the fermentation broth prior to making monomer of a suitable quality and indeed using the monomer in the

5 manufacture of commercial grade polymers. Furthermore, the process preferably avoids the step of removing the biocatalyst from the monomer prior to polymerisation. In addition the monomer can for instance be produced as a product of a fermentation and the monomer produced in this way does not have to be isolated from the fermentation broth prior to polymerisation.

10 Consequently the process of the present invention can avoid the need for expensive separation equipment for the removal of the biocatalyst; either microbial whole or fractured cells, which may be used to remove the catalyst from a fermentation broth or for the removal of the catalyst after the monomer
15 product has been made. Furthermore there would be no need to purify the monomer prior to polymerisation.

The biocatalyst should be capable of converting a substrate into the desired monomer. Generally it would be a microorganism that is capable of generating enzymes suitable for the conversion. For instance this could be a
20 microorganism selected from a wide number of microbial genera. These could include microorganisms selected from the genus *Bacillus*, *Bacteridium*, *Micrococcus*, *Brevibacterium*, *Corynebacterium*, *Pseudomonas*, *Acinetobacter*, *Xanthobacter*, *Streptomyces*, *Rhizobium*, *Klebsiella*, *Enterobacter*, *Erwinia*,
25 *Aeromonas*, *Citrobacter*, *Achromobacter*, *Agrobacterium*, *Pseudonocardia*, *Rhodococcus*, *Comomonas*, *Candida* and *Fusarium*.

Preferred microorganisms include those which provide enzymes that are useful in catalysing the production of itaconic acid, maleic acid and acrylic acid or salts thereof as part of their metabolic processes. Additionally those microorganisms that produce monomers by catalysing the substrate compounds lactic acid, 3-

hydroxpropionic acid, and glycerol, which are then reacted in further processes to give ethylenically unsaturated monomer. Other preferred microorganisms include those that are capable of producing enzymes that convert nitriles into the corresponding amides or carboxylic acids. Also preferred are those

- 5 microorganisms that can produce nitrilase suitable for converting (meth) acrylonitrile to (meth) acrylate, for instance those of the genus *Rhodococcus*. Particularly preferred microorganisms are those that can produce nitrile hydratase suitable for converting (meth) acrylonitrile to (meth) acrylamide, for instance those of the *Rhodococcus* genus, especially the *Rhodococcus* rhodochrous species. A particularly suitable biocatalyst is the novel *Rhodococcus* rhodochrous strain 2368 (NCIMB 41164) which is described and claimed in our co-filed UK patent application which has been allocated case reference number BT/3-22351/P1.

15 *Rhodococcus* rhodochrous strain 2368

1. Origin and Deposition

The strain 2368 was isolated by us from soil in Bradford, England and deposited on 5th March 2003 at the National Collection of Industrial and Marine Bacteria (NCIMB), where it was assigned the accession number NCIMB 41164 under the

20 Budapest Treaty.

2. Morphological and cultural characteristics

(1) Polymorphic growth

(2) Motility: immotile

(3) Non-spore former

25 (4) Gram positive

(5) Aerobic

(6) Growth on nutrient agar gives salmon pink round colonies within 48 hours at 30°C.

- The biocatalyst comprises cellular material in the form of whole cells or fractured cells and optionally comprises fermentation broth. The cellular material may include any of the constituents of a microbial cell, for instance including cell wall material, cell nucleic acid material (for instance DNA or RNA), cytoplasm or proteins. Generally the amount of cellular material presence in the monomer will be at least 0.001% by weight and usually at least 0.005% by weight.
- 5
- The fermentation broth may include any of the typical ingredients used for culturing the microorganism and also may include products and by-products produced by the microorganism. Typical components of the fermentation broth include sugars, polysaccharides, proteins, peptides, amino acids, nitrogen sources, inorganic salts, vitamins, growth regulators and enzyme inducers. Specifically this could include monosaccharides or disaccharides as sugars; 10 ammonium salts or other nitrogen sources; inorganic salts such as phosphates, sulphates, magnesium, calcium, sodium and potassium salts; metal compounds; vitamins; and complex fermentation medium components, for example corn steep liquor; peptone; yeast extract; organic or inorganic compounds that may be used for specific microbial growth requirements; 15 specific enzyme inducers; and organic acids such as citrate or pyruvate; and any other organic or inorganic compounds that may be required to ensure successful growth of the specific microorganism.
- 20
- The ethylenically unsaturated monomer may be any such substance that can be prepared biologically from a starting material or specific substance, which is termed a substrate. Desirably the monomer includes ethylenically unsaturated amides, N-substituted amides, carboxylic acids, carboxylic acid esters, amines including free amines, primary, secondary, tertiary amines and quaternary ammonium compounds. Preferably the monomer is acrylic. Also preferably the 25 ethylenically unsaturated monomer is soluble in water. By soluble in water we mean that the monomer has a solid ability of at least 5 g per 100 ml at 25°C.
- 30

More preferably the ethylenically unsaturated monomer is acrylamide or methacrylamide. Other preferred monomers include itaconic acid (or salts thereof), maleic acid (or salts thereof) and acrylic acid (or salts thereof).

- 5 -The ethylenically unsaturated monomer can be used in the process alone to form the homopolymer or can be mixed with other ethylenically unsaturated monomers to form a monomer mixture that is polymerised to form a copolymer of the ethylenically unsaturated monomer. Any suitable co-monomer may be used for this purpose. Especially where the ethylenically unsaturated monomer
10 is water-soluble. The co-monomer should desirably be water-soluble or potentially water-soluble, such as anhydrides. Typical co-monomers include (meth) acrylamide, (meth) acrylic acid (or salts), itaconic acid (or salts), maleic acid (or salts), maleic anhydride, vinyl sulfonic acid (or salts), allyl sulfonic acid (or salts), 2-acrylamido-2-methyl propane sulfonic acid (or salts), dimethyl
15 amino ethyl (meth) acrylate (or quaternary ammonium salts), dimethyl amino propyl (meth) acrylamide (or quaternary ammonium salts), N-vinyl pyrrolidone, N-vinyl formamide, vinyl acetate, acrylonitrile, (meth) acrylic esters of C₁₋₃₀ alcohols. The salts of the above stated acid monomers may be of any suitable cation but preferably alkali metal or ammonium salts.
- 20 The process of the present invention is particular suitable for preparing high molecular weight water-soluble or water swellable polymers. The polymers may for instance be linear, branched or cross-linked. Preferably the polymers are high molecular weight substantially water-soluble that exhibit an intrinsic viscosity (IV) of at least 3 dl/g (measured using a suspended level viscometer in 1M sodium chloride at 25°C). Usually the polymers will have intrinsic viscosities of at least 4 dl/g and generally significantly higher, for instance at least 7 or 8 dl/g. In many cases the polymers will have IV's of at least 10 or 12 dl/g and could be as high as 20 or 30 dl/g.

The water-soluble or water-swellable polymer prepared according to the process of the present invention may be cationic, anionic, non-ionic or amphoteric. It may be substantially linear or alternatively branched or cross-linked. Cross-linked or branched polymers are prepared by incorporating a branching or cross-linking agent into the monomer blend. The cross-linking or branching agent may be for instance a di- or multifunctional material that reacts with functional groups pendant on the polymer chain, for instance multivalent metal ions or amine compounds which can react with pendant carboxylic groups. Preferably, however, the cross-linking or branching agent will be a polyethylenically unsaturated compound, which becomes polymerised into two or more polymer chains. Typically such cross-linking agents include methylene-bis-acrylamide, tetra allyl ammonium chloride, triallyl amine and polyethylene glycol di acrylate. The polymers may be highly crosslinked and therefore water insoluble but water swellable. Alternatively the polymer may be water soluble and either substantially linear or slightly branched, for instance prepared using less than 10 ppm cross-linking/branching monomer.

Particularly preferred polymers made by the process of the invention include homopolymers or copolymers of acrylamide or methacrylamide. Desirably the copolymers include any of the above stated co-monomers but preferably it is a copolymer of acrylamide with sodium acrylate or a copolymer of acrylamide with quaternary ammonium and acid salts of dimethylaminoethyl(meth)acrylate. Especially preferred acrylamide homo or copolymers are of high molecular weight and exhibit high intrinsic viscosity as defined above.

The polymer is generally formed by subjecting the ethylenically unsaturated monomer or a monomer mixture comprising the ethylenically unsaturated monomer to polymerisation conditions. This may be achieved by heating or irradiation, for instance using ultraviolet light. Preferably polymerisation initiators are introduced into the monomer or mixture of monomers to initiate polymerisation. Desirably this may be achieved by the use of redox initiators

and/or thermal initiators. Typically redox initiators include a reducing agent such as sodium sulphite, sulphur dioxide and an oxidising compound such as ammonium persulphate or a suitable peroxy compound, such as tertiary butyl hydroperoxide etc. Redox Initiation may employ up to 10,000 ppm (based on

- 5 weight of monomer) of each component of the redox couple. Preferably though each component of the redox couple is often less than 1000 ppm, typically in the range 1 to 100 ppm, normally in the range 4 to 50 ppm. The ratio of reducing agent to oxidizing agent may be from 10:1 to 1:10, preferably in the range 5:1 to 1:5, more preferably 2:1 to 1:2, for instance around 1:1.

10

Polymerisation may also be effected by employing a thermal initiation alone or in combination with other initiator systems, for instance redox initiators. Thermal initiators would include any suitable initiator compound that releases radicals at an elevated temperature, for instance azo compounds, such as

- 15 azobisisobutyronitrile (AZDN), 4,4'-azobis-(4-cyanovaleric acid) (ACVA).

Typically thermal initiators are used in an amount of up 10,000 ppm, based on weight of monomer. In most cases, however, thermal initiators are used in the range 100 to 5,000 ppm preferably 200 to 2,000 ppm, usually around 1,000 ppm.

20

Typically an aqueous solution of water soluble monomer may be polymerised by solution polymerisation to provide an aqueous gel or by reverse phase polymerisation in which an aqueous solution of monomer is suspended in a water immiscible liquid and polymerised to form polymeric beads or alternatively

- 25 by emulsifying aqueous monomer into an organic liquid and then effecting [Kc2]polymerisation. Examples of reverse phase polymerisation are given in EP-A-150933, EP-A-102760 or EP-A-126528.

- 30 In a further aspect of the invention in that the ethylenically unsaturated monomer can be produced by the biocatalyst, optionally mixed with other monomers, and then polymerised in situ to form the polymer. Consequently the

ethylenically unsaturated monomer may be produced and then polymerised in the same vessel. Thus the ethylenically unsaturated monomer is produced from the substrate in a vessel, optionally other monomers are introduced into the vessel to form a monomer mixture. The ethylenically unsaturated monomer or monomer mixture is then subjected to polymerisation conditions, optionally by introducing initiators into the vessel, and thereby forming the polymer inside the vessel. Furthermore, the process can be more conveniently adapted by producing the biocatalyst in the same vessel, introducing the substrate into the vessel which is then converted into the ethylenically saturated monomer and 10 then polymerised in the same vessel to form the polymer as defined above.

Thus the process of the present invention provides the advantages of avoiding the need for removing the cells from the catalytic broth or to remove impurities or cellular material from the monomer. Additionally the product made by this 15 process is a novel composition.

The following examples illustrate the invention.

20 Example 1

Rhodococcus rhodochrous NCIMB 41164 is grown in a 280L fermenter containing 180 L culture medium containing the following constituents (g/L): dipotassium hydrogen phosphate 0.7; potassium hydrogen phosphate 0.3; 25 glucose 1.0; urea, 5.0; yeast extract 3.0; magnesium sulphate heptahydrate 0.5; cobalt chloride hexahydrate 0.01;. The pH of the medium is adjusted to pH 7.2. The culture is grown at 30°C for 3 days. Glucose is also fed to the culture periodically.

30 The nitrile hydratase activity of the fermentation broth is measured 15 h after harvesting and it is found to be 242,000 U/g at 25°C (700,000 U/L).

15 L of the above fermentation broth is mixed with 35 L process water, this suspension is then charged to a 600 L reactor that contained 250 kg water. Acrylonitrile is fed to the reactor over a period of several hours until an acrylamide concentration of 46.8% is achieved. 25 kg of the acrylamide 5 solution is centrifuged to remove the biocatalyst. 25 kg of the acrylamide was not centrifuged to remove the biocatalyst.

The centrifuged and non-centrifuged acrylamide samples are polymerized as homo-polymers using redox and thermal initiators to give gel polymers with IV of 10 approx. 17 dL/g. The viscosity in cP was also measured and there was no differences in the samples prepared using both centrifuged and un-centrifuged material.

17

Example 2

- A 50% (w/w) acrylamide solution containing up to 20% by weight of
fermentation broth of microorganism *Rhodococcus rhodochrous* NCIMB 41164
5 is prepared. The acrylamide doped with fermentation broth is polymerized as a
homo-polymer using redox and thermal initiators to form a gel polymer with IV of
approx 17 dl/g.

10

15

Claims


1. A process for preparing a polymer of an ethylenically unsaturated monomer, in which the monomer is obtainable from a biocatalysed reaction or a fermentation process, and wherein the monomer contains cellular material and/or components of a fermentation broth,
5 forming the polymer by polymerising the ethylenically unsaturated monomer or a monomer mixture comprising the ethylenically unsaturated monomer, wherein there is substantially no removal of the cellular material and/or components of the fermentation broth from the ethylenically unsaturated
10 monomer.
2. A process according to claim 1 in which the ethylenically unsaturated monomer is prepared by providing a substrate that can be converted into the ethylenically unsaturated monomer,
contacting the substrate with a biocatalyst and thereby converting the substrate
15 into the ethylenically unsaturated monomer containing the cellular material and optionally components of a fermentation.
3. A process according to claim 1 or claim 2 in which the cellular material comprises whole cells.
4. A process according to any of claims 1 to 3 in which the cellular material
20 comprises fractured cellular material.
5. A process according to claim 4 in which the fractured cellular material is selected from the group consisting of cell wall material, cell nucleus material, cytoplasm and proteins.
6. A process according to any of claims 1 to 5 in which the components of
25 the fermentation broth are selected from the group consisting of sugars, polysaccharides, proteins, peptides, amino acids, nitrogen sources, inorganic salts, vitamins, growth regulators and enzyme inducers.
7. A process according to any of claims 1 to 6 in which the ethylenically unsaturated monomer is (meth)acrylamide monomer.
- 30 8. A process according to any of claims 2 to 7 in which the substrate is (meth)acrylonitrile.

9. A process according to any of claims 2 to 8 in which the biocatalyst comprises a nitrile hydratase enzyme.
10. A process according to any of claims 1 to 9 in which the polymer is a homopolymer or copolymer of (meth) acrylamide.
- 5 11. A process according to any of claims 1 to 6 in which the ethylenically unsaturated monomer is selected from the group consisting of itaconic acid (or salts thereof), maleic acid (or salts thereof) and (meth) acrylic acid (or salts thereof).
- 10 12. A process according to any of claims 2 to 6 or claim 11 in which the substrate is selected from the group consisting of lactic acid, 3-hydroxpropionic acid, and glycerol.
13. A process according to any of claims 2 to 8 in which the substrate is introduced into a vessel and contacted with a biocatalyst and wherein the substrate is converted into the ethylenically unsaturated monomer,
- 15 14. optionally introducing other monomers into the vessel to form a monomer mixture, subjecting the ethylenically unsaturated monomer or monomer mixture to polymerisation conditions, optionally by introducing initiators into the vessel, and thereby forming the polymer inside the vessel.
16. A process according to claim 13 in which the biocatalyst is produced in the vessel.
17. A process according to any of claims 2 to 14 in which the biocatalyst comprises microorganisms of the Rhodococcus genus, preferably species Rhodococcus rhodochrous.
- 20 18. A process according to claim 15 in which the microorganism is Rhodococcus rhodochrous NCIMB 41164.
- 25 19. A composition comprising a polymer of an ethylenically unsaturated monomer and further comprising cellular material and/or components of a fermentation broth, wherein the composition is obtainable by a process according to any of claims 1 to 16.

Abstract**Process for Producing Polymers**

A process for preparing a polymer of an ethylenically unsaturated monomer, in which the monomer is obtainable from a biocatalysed reaction or a fermentation 5 process, and wherein the monomer contains cellular material and/or components of a fermentation broth, forming the polymer by polymerising the ethylenically unsaturated monomer or a monomer mixture comprising the ethylenically unsaturated monomer, wherein there is substantially no removal of the cellular material and/or 10 components of the fermentation broth from the ethylenically unsaturated monomer.

PCT/EP2004/013250



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.